Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance

Tytuł:
Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance
Autorzy:
Marc Llagostera-Martín
Hector Cubero-Gallego
Aleksandra Mas-Stachurska
Neus Salvatella
Andrea Sánchez-Carpintero
Helena Tizon-Marcos
Marcos Garcia-Guimaraes
Alicia Calvo-Fernandez
Luis Molina
Beatriz Vaquerizo
Temat:
left atrial appendage closure
atrial fibrillation
stroke
LAmbre
Medicine
Źródło:
Journal of Clinical Medicine, Vol 10, Iss 7, p 1421 (2021)
Wydawca:
MDPI AG, 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Medicine
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2077-0383
Relacje:
https://www.mdpi.com/2077-0383/10/7/1421; https://doaj.org/toc/2077-0383
DOI:
10.3390/jcm10071421
Dostęp URL:
https://doaj.org/article/1a86342349ae4e66a27554215d1d63be  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.1a86342349ae4e66a27554215d1d63be
Czasopismo naukowe
The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbreTM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9.4 years), with a high proportion of comorbidities. The mean CHA2DS2-VASc and HAS-BLED scores were 4.6 ± 1.6 and 3.9 ± 1.0, respectively. Previous history of a major bleeding event was present in 37 patients (67.3%). Procedural success was achieved in 54 patients (98.2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1.8%) and pericardial tamponade in two patients (3.6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1.8%), transient ischemic attack/ischemic stroke (1.8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbreTM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies